Biosecure Act influence still felt even as China bill stallsnews2024-12-18T19:41:08+00:00December 18th, 2024|Endpoints News|
Merck’s long-awaited obesity move is an oral GLP-1 from Chinanews2024-12-18T15:18:50+00:00December 18th, 2024|Endpoints News|
The Endpoints 100 Survey: Biotech industry braces for Trump 2.0news2024-12-11T12:00:55+00:00December 11th, 2024|Endpoints News|
Exclusive: Angitia, a Bain-backed musculoskeletal biotech, raises $120M for trio of clinical-stage biologicsnews2024-12-11T12:00:35+00:00December 11th, 2024|Endpoints News|
Biosecure bill is left out of end-of-year defense packagenews2024-12-08T02:00:38+00:00December 8th, 2024|Endpoints News|
GSK makes another ADC deal, this time with BioNTech’s partner DualityBionews2024-12-04T08:28:36+00:00December 4th, 2024|Endpoints News|
Sanofi earmarks €1B for new insulin production factory in Beijing news2024-12-02T19:00:06+00:00December 2nd, 2024|Endpoints News|
Exclusive: Athena Countouriotis’ Avenzo taps Shanghai biotech for ADC, adds new fundsnews2024-11-18T12:00:27+00:00November 18th, 2024|Endpoints News|
BeiGene rebrands as BeOne Medicines, dropping name’s link to Chinanews2024-11-14T15:05:14+00:00November 14th, 2024|Endpoints News|
Merck buys into PD-1/VEGF space as Summit comes for Keytrudanews2024-11-14T12:29:52+00:00November 14th, 2024|Endpoints News|
